DRREDDY — Dr. Reddy's Laboratories Share News
0.000.00%
Last trade - 00:00- IN₹1.02tn
- IN₹1.01tn
- IN₹337.00bn
Advisory: Inadvertently published alert on NYSE tagged to multiple companies withdrawn
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry (updated)
Hims offers Apotex's generic semaglutide in Canada after Novo patent expiry
Brief: Dr Reddy's Launches Oral Semaglutide Biosimilar Obeda In India
Pfizer's India unit drops on quarterly profit fall
Street View - India's Dr Reddy's facing pricing pressure and competition
Preview: India's Cipla slips ahead of quarterly results on concerns over weak US sales
Brief: India's Dr Reddy's Looking To Launch Semaglutide In Canada In Next Few Days In This Month
Indian drugmaker Dr Reddy's quarterly profit slumps on cancer therapy impairments (updated)
Brief: Dr Reddy's Got Marketing Authorization For Generic Semaglutide Tablets In India From Dcgi
Indian drugmaker Dr Reddy's posts quarterly profit slump
Brief: Dr. Reddy's Q4 Consol Net PAT 2.21 Billion Rupees; IBES Est. 9.25 Billion Rupees
Preview: 'Challenging Q4' for Indian pharma firm Dr Reddy's, analysts say
India's pharma stocks log best week since March 2025 on strong earnings, April sales
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Press Digest: Canada - April 29
Brief: Dr Reddy's Receives Health Canada Approval For Semaglutide Injection
Health Canada approves first generic version of Novo Nordisk's Ozempic (updated)
Health Canada approves first generic version of Novo Nordisk's Ozempic